Researchers from MIT have developed a new type of insulin which activates in the bloodstream only when it is needed. The development could make everyday life much easier for type 1 diabetes patients. [ + ]

Mesoblast (ASX:MSB) reported a 64% higher net loss for the half-year ending in December, but still ended the period in a strong cash position of $149.2m. [ + ]

It's no secret that honey bee populations have been rapidly declining of late. An international group of scientists, including Australians, thinks the cause of this collapse lies in young bees who are growing up too fast.

Prescient (ASX:PTX) has acquired the exclusive global rights to the p27 biomarker and plans to develop it as a companion diagnostic to cancer drug candidate PTX-100. [ + ]

Patrys (ASX:PAB) expects to have to delay a planned trial of PAT-SM6 in multiple myeloma due to issues surrounding the manufacture of materials for the study. [ + ]

Researchers from the US and China have discovered a structural variant of carbon called 'penta-graphene' - a very thin sheet of pure carbon that resembles the pentagonal pattern of the tiles which pave the streets of Cairo. [ + ]

Anthrax and Bubonic plague were among the 637 known bacterial, viral, fungal and animal species identified in the New York City Subway system. Only 12% of the bacteria species sampled are known to have some association with disease, but more interestingly still, 48.3% of the DNA sampled did not match any known organism.

Researchers from the US and China have discovered a structural variant of carbon called 'penta-graphene' - a very thin sheet of pure carbon that resembles the pentagonal pattern of the tiles which pave the streets of Cairo. [ + ]

Invion (ASX:IVX) has completed recruitment in a trial of INV102 in smoking cessation for chronic bronchitis patients, shortly after announcing positive interim results. [ + ]

"What's in a name?" was essentially the Australian government's response when concerns were first expressed about dropping "Science" from the ministerial portfolio titles back in 2013. [ + ]

The Institute of Bioengineering and Nanotechnology (IBN) at A*STAR has developed a paper-based disposable device that will allow dengue-specific antibodies to be detected easily from saliva within 20 min. [ + ]

Novogen (ASX:NRT) has completed placements to ensure it regains compliance with Nasdaq listing rules, while CEO Dr Graham Kelly prepares to present at two investor conferences over the next two weeks. [ + ]

Bionomics (ASX:BNO) has commenced a phase Ib trial of BNC210, its anxiety and depression drug candidate, and is laying the groundwork for a phase IIa trial due to begin this quarter. [ + ]

Shares in Genetic Technologies (ASX:GTG) more than doubled after the company revealed that up to six new breast centres will stock its BREVAGen breast cancer risk test in Q1, with more contracts on the way. [ + ]

Scientists have announced the release of Aquaria - a publicly available web resource that streamlines and simplifies the process of gleaning insight from 3D protein structures. [ + ]